Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the CABOSUN study in renal cell carcinoma (RCC).
The CABOSUN study randomized more than 150 patients between sunitinib (Sutent) and cabozantinib (Cabometyx). These individuals had intermediate- and poor-risk features. The progression-free survival (PFS) for cabozantinib was clearly superior to that of sunitinib, states Jonasch.
According to Jonasch, a number of individuals who were on sunitinib came off very early in the study, which may have skewed the curves somewhat in favor of cabozantinib.